Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ningbo Tai Kang Medical Technology
Ningbo, Zhejiang, Chinanbhds.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Company holds exclusive global rights from AstraZeneca for AZD3229, a small molecule KIT/PDGFRα inhibitor in development for GIST. Clinical data not disclosed publicly; preclinical data reportedly show efficacy and favorable safety.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
AstraZeneca (global licensing of AZD3229)
Beyond the preview
Go deeper on Ningbo Tai Kang Medical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ningbo Tai Kang Medical Technology.